Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Bakhos A. Tannous, Ph.D.

Co-Author

This page shows the publications co-authored by Bakhos Tannous and Litia Carvalho.
Connection Strength

2.347
  1. Olfactory ensheathing cells travel their natural nasal pathway to deliver therapeutics to brain tumors. Oncotarget. 2019 07 09; 10(43):4351-4353.
    View in: PubMed
    Score: 0.846
  2. Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy. J Natl Cancer Inst. 2019 03 01; 111(3):283-291.
    View in: PubMed
    Score: 0.825
  3. Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy. ACS Nano. 2019 04 23; 13(4):4028-4040.
    View in: PubMed
    Score: 0.207
  4. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Neuro Oncol. 2018 04 09; 20(5):642-654.
    View in: PubMed
    Score: 0.194
  5. Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase. Sci Rep. 2016 05 20; 6:26353.
    View in: PubMed
    Score: 0.170
  6. Erratum: Author Correction: Sustained NF-?B-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a vulnerability to EZH2 inhibition. Cell Death Discov. 2019; 5:103.
    View in: PubMed
    Score: 0.053
  7. Sustained NF-?B-STAT3 signaling promotes resistance to Smac mimetics in Glioma stem-like cells but creates a vulnerability to EZH2 inhibition. Cell Death Discov. 2019; 5:72.
    View in: PubMed
    Score: 0.052
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.